Abstract: The invention relates to recombinant fusion proteins comprising a fibrinogenolytic enzyme having an amino acid sequence that is C-terminally and/or N-terminally linked to the amino acid sequence of at least one high-molecular inert stabilization domain with a molecular weight of >50 kDa, for the prevention or treatment of adhesions at tissues or organs, in particular peritoneal adhesions following surgical interventions.

Abstract: The invention relates to recombinant fusion proteins comprising a fibrinogenolytic enzyme having an amino acid sequence that is C-terminally and/or N-terminally linked to the amino acid sequence of at least one high-molecular inert stabilization domain with a molecular weight of >50 kDa, for the prevention or treatment of adhesions at tissues or organs, in particular peritoneal adhesions following surgical interventions.

Abstract: The invention relates to recombinant fusion proteins comprising a fibrinogenolytic enzyme having an amino acid sequence that is C-terminally and/or N-terminally linked to the amino acid sequence of at least one high-molecular inert stabilization domain with a molecular weight of >50 kDa, for the prevention or treatment of adhesions at tissues or organs, in particular peritoneal adhesions following surgical interventions.

Abstract: Hirudin/polyalkylene glycol derivatives of the formula[A--(CH.sub.2).sub.n --[O--(CH.sub.2).sub.nlm --B--].sub.p Hir [sic]Iand hirudin muteins and the preparation thereof are described. The compounds are suitable for controlling diseases.

Abstract: 2-alkyl-4-arylmethylaminoquinolines of the general formula I ##STR1## where R.sup.1, R.sup.2, R.sup.5 and R.sup.6 have the meanings specified in the claims, and the physiologically tolerated salts thereof, the use thereof for the preparation of drugs and the drugs thus obtained as described for the inhibition of gastric acid secretion.

Abstract: Sulfonamide derivatives of the formula I ##STR1## where R.sup.1 is a C.sub.1 -C.sub.4 -alkyl or phenyl group which may be substituted by halogen, trifluoromethyl or C.sub.1 -C.sub.4 -alkyl, R.sup.2 is hydrogen or C.sub.1 -C.sub.4 -alkyl, A is a group CHOR.sup.3 C.dbd.O, C.dbd.S or C.dbd.N--OR.sup.4, R.sup.3 is hydrogen, C.sub.1 -C.sub.4 -alkyl phenyl, benzyl or C.sub.1 -C.sub.4 -acyl, R.sup.4 is hydrogen or methyl, B may be methylene or ethylene in the m or p position or, of A is not carbonyl, may be methyleneoxy, the oxygen atom being bonded to the aromatic, and E is a carboxyl, phosphonic acid or sulfo radical, their physiologically acceptable salts, esters with C.sub.1 -C.sub.4 -alcohols or amides or the tetrazol-5-yl radical, their preparation and their use as drugs.

Abstract: A mixture of a substance having thrombolytic activity and of an antithrombotic substance which is suitable for controlling vascular disorders caused by thrombosis is described.

Abstract: Benzofuran derivatives of the general formula I ##STR1## where R.sup.1 and R.sup.2 are each hydrogen, alkyl or phenylalkyl, where alkyl in each case is of 1 to 4 carbon atoms, R.sup.3 and R.sup.4 are identical or different and are each hydrogen or C.sub.1 -C.sub.4 -alkyl or together form a 3-membered to 5-membered chain which may be interrupted by an oxygen atom or an NR.sup.1 group, X is --CO--CH.dbd.CH--, --CO--CH.sub.2 --CH.sub.2 --or --CHOH--CH.sub.2 --CH.sub.2 --, n is 2 or 3 and Het is an aromatic 5-membered or 6-membered ring which contains a hetero atom from the group consisting of N, O and S and may additionally contain a (further) N atom, in which the ring may be substituted by C.sub.1 -C.sub.4 -alkyl, fluorine, chlorine, bromine, NH.sub.2 or NR.sup.1 R.sup.2, where R.sup.1 and R.sup.2 have the abovementioned meanings, the use of these benzofuran derivatives for the preparation of pharmaceutical, in particular antiulcerogenic, agents, and these agents themselves are described.

Abstract: Phenylacetaldehydes which are substituted by basic groups, of the formula ##STR1## where R.sup.1 to R.sup.8, m and n have the meanings stated in the description, and their preparation are described. The substances are useful for the treatment of disorders.

Abstract: Novel pyrrol-1-ylphenyldihydropyridazinones of the formula ##STR1## their preparation and their use in the treatment of disorders.